Summary of Study ST003185

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001983. The data can be accessed directly via it's Project DOI: 10.21228/M8D72S This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST003185
Study Title	A multimodal drug-diet-immunotherapy combination restrains melanoma progression and metastasis - plasma lipidomics
Study Summary	Lipidomics profiling of immunocompetent B16F10 model of melanoma to examine lipid levels in mouse plasma following reduced oleic acid content in diet combined with the stearyl CoA desaturase inhibitor CAY10566.
Institute	University of Colorado Anschutz Medical Campus
Last Name	Haines
First Name	Julie
Address	12801 E 17th Ave, Room 1303, Aurora, Colorado, 80045, USA
Email	julie.haines@cuanschutz.edu
Phone	3037243339
Submit Date	2024-05-02
Raw Data Available	Yes
Raw Data File Type(s)	raw(Thermo)
Analysis Type Detail	LC-MS
Release Date	2024-05-18
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR003313
Treatment Summary:	All animal procedures were carried out in accordance with the IACUC-approved protocol of Cincinnati Children’s Hospital Medical Center. Animals were monitored daily by Veterinary Services. For subcutaneous tumor implantation, 1x10^6 B16F10 cells were mixed with matrigel 1:1 and implanted subcutaneously into NOD-SCID IL2Rgnull or C57BL/6 mice, respectively. CAY10566 was suspended in 0.5% Methyl Cellulose in water with 0.2% Tween 80 at 9 parts per 1 part DMSO stock. CAY10566 was administered at 30mg/kg via oral gavage, twice daily, with a drug holiday during the weekends. Treatment began three days after tumor cell implantation (bilateral tumors in n=4 per group). Mice were euthanized17 days after tumor cell injection/14 days after the start of treatment.

Treatment ID:

TR003313

Treatment Summary:

All animal procedures were carried out in accordance with the IACUC-approved protocol of Cincinnati Children’s Hospital Medical Center. Animals were monitored daily by Veterinary Services. For subcutaneous tumor implantation, 1x10^6 B16F10 cells were mixed with matrigel 1:1 and implanted subcutaneously into NOD-SCID IL2Rgnull or C57BL/6 mice, respectively. CAY10566 was suspended in 0.5% Methyl Cellulose in water with 0.2% Tween 80 at 9 parts per 1 part DMSO stock. CAY10566 was administered at 30mg/kg via oral gavage, twice daily, with a drug holiday during the weekends. Treatment began three days after tumor cell implantation (bilateral tumors in n=4 per group). Mice were euthanized17 days after tumor cell injection/14 days after the start of treatment.